397843-09-3Relevant articles and documents
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors
Cullen, Matthew D.,Cheung, York-Fong,Houslay, Miles D.,Hartman, Tracy L.,Watson, Karen M.,Buckheit Jr., Robert W.,Pannecouque, Christophe,De Clercq, Erik,Cushman, Mark
, p. 1530 - 1533 (2008/09/19)
The alkenyldiarylmethanes (ADAMs) are currently being investigated as non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) of potential value in the treatment of HIV infection and AIDS. During the course of these studies, a number of ADAM analog
Synthesis and anti-HIV activity of a bile acid analog of cosalane
Kannan, Arunachalam,De Clercq, Erik,Pannecouque, Christophe,Witvrouw, Myriam,Hartman, Tracy L,Turpin, Jim A,Buckheit Jr., Robert W,Cushman, Mark
, p. 9385 - 9391 (2007/10/03)
Cosalane is a novel anti-HIV agent that inhibits the attachment of gp120 to CD4. The therapeutic potential of cosalane is limited by poor oral absorption. In an attempt to target the ileal bile acid transporter and thus facilitate oral bioavailability, a cosalane analog was synthesized in which the disalicylmethane pharmacophore is attached to a bile acid through a linker chain appended to C-17 of the steroid nucleus. The resulting bile acid analog of cosalane retained antiviral activity vs. HIV-1IIIB and HIV-2ROD in MT-4 cells, but was less potent than cosalane.